This effect of sorafenib therapy might be dependent on two mechanisms, which are (1) induction of antigen-primed CD4+ T helper cells after recognition of MICA expression by HCC cells and (2) a decrease of Treg cells related to inhibition of tumor neoangiogenesis. Here, CD4 is linked to hepatocellular carcinoma.